Special Centre for Molecular Medicine , Jawaharlal Nehru University , New Delhi 110067 , India.
Biochemistry. 2019 Feb 12;58(6):809-817. doi: 10.1021/acs.biochem.8b01102. Epub 2019 Jan 10.
DNA topoisomerases are unique enzymes that alter the topology of DNA by cleavage and religation mechanisms. Small molecules such as camptothecins and noncamptothecins are reported to inhibit different classes of topoisomerases. Benzimidazole, 2-(3,4-dimethoxyphenyl)-5-[5-(4-methylpiperazin-1-yl)-1 H-benzimidazol-2-yl]-1 H benzimidazole (DMA), a new analogue of Hoechst 33342, was observed as a selective and differential inhibitor of human and Escherichia coli DNA topoisomerase I. In this study, we have concluded that DMA and Hoechst 33342 have differential binding toward human and E. coli topoisomerase I. We also dissected the mechanism of differential binding, as DMA and Hoechst 33342 bind to human topoisomerase I with linear kinetics with reversible binding, whereas the same molecules bind to E. coli topoisomerase I in a nonlinear and irreversible manner, which contributes to higher affinity and comparatively good IC values toward E. coli topoisomerase I. Interestingly, DMA and Hoechst 33342 showed inhibition of mutant human topoisomerases I, i.e., A653P, N722S, and T729P, whereas these clinically relevant mutants are resistant to camptothecins.
DNA 拓扑异构酶是通过切割和连接机制改变 DNA 拓扑结构的独特酶。据报道,小分子如喜树碱和非喜树碱能够抑制不同类型的拓扑异构酶。苯并咪唑,2-(3,4-二甲氧基苯基)-5-[5-(4-甲基哌嗪-1-基)-1H-苯并咪唑-2-基]-1H-苯并咪唑(DMA),是 Hoechst 33342 的一种新型类似物,被观察为人类和大肠杆菌 DNA 拓扑异构酶 I 的选择性和差异抑制剂。在这项研究中,我们得出结论,DMA 和 Hoechst 33342 对人类和大肠杆菌拓扑异构酶 I 的结合具有差异。我们还剖析了差异结合的机制,因为 DMA 和 Hoechst 33342 与人拓扑异构酶 I 的结合具有线性动力学和可逆结合,而相同的分子与大肠杆菌拓扑异构酶 I 的结合是非线性和不可逆的,这有助于对大肠杆菌拓扑异构酶 I 具有更高的亲和力和相对较好的 IC 值。有趣的是,DMA 和 Hoechst 33342 抑制了突变型人类拓扑异构酶 I,即 A653P、N722S 和 T729P,而这些临床上相关的突变体对喜树碱具有抗性。